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Abstract Alzheimer’s disease (AD) is reaching epidemic
proportions, yet a cure is not yet available. While the
genetic causes of the rare familial inherited forms of AD
are understood, the causes of the sporadic forms of the
disease are not. Histopathologically, these two forms of AD
are indistinguishable: they are characterized by amyloid-b
(Ab) peptide-containing amyloid plaques and tau-contain-
ing neurofibrillary tangles. In this review we compare AD
to frontotemporal dementia (FTD), a subset of which is
characterized by tau deposition in the absence of overt
plaques. A host of transgenic animal AD models have been
established through the expression of human proteins with
pathogenic mutations previously identified in familial AD
and FTD. Determining how these mutant proteins cause
disease in vivo should contribute to an understanding of the
causes of the more frequent sporadic forms. We discuss the
insight transgenic animal models have provided into Ab
and tau toxicity, also with regards to mitochondrial func-
tion and the crucial role tau plays in mediating Ab toxicity.
We also discuss the role of miRNAs in mediating the toxic
effects of the Ab peptide.
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Introduction
One of the major burdens associated with advanced age is
dementia, a pathological condition defined as the signifi-
cant loss of intellectual abilities—such as memory
functions—that is severe enough to interfere with social or
occupational functioning. The relentless neuronal degen-
eration that is associated with Alzheimer’s disease (AD)
and the more than two dozen related disorders affects a
steadily increasing percentage of the population world-
wide. More than 26 million people worldwide are currently
living with AD, a number that will quadruple to more than
106 million by 2050 unless effective treatments or a cure
are found. Of all dementing disorders, AD is the most
common form, comprising 50–70% of all reported cases.
Frontotemporal dementia (FTD), in comparison, is less
frequent, but may account for up to 50% of all dementia
cases presenting before the age of 60 years [1]. At the
present time, neither AD nor FTD can be cured although
lifestyle choices, such as of diet and exercise, confer some
form of protection [2].
Neuropathological features of AD and FTD
When in the years of 1992 and 1997, the 100-year-old
histological slides of Alois Alzheimer’s original cases were
rediscovered in the basement of the Institute of Neuropa-
thology of the University of Munich [3], they revealed
what Alzheimer had described in his first case, Auguste D,
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as the key features of the disease named after him: the
presence of overt neurofibrillary tangles (NFTs) and amy-
loid plaques. While Alzheimer was the first to describe
NFTs [4], the credit of reporting amyloid plaques for the
first time goes to Fischer and Redich [5]. Plaques and NFTs
are the key histopathological hallmarks of AD (Fig. 1). The
AD brain is further characterized by massive neuronal cell
and synapse loss at specific predilection sites [6]. The
major proteinaceous component of the plaques is a 40–42
amino acid polypeptide amyloid-b (Ab; (Ab40 and Ab42)
that is derived by proteolytic cleavage from the larger
amyloid precursor protein APP [7, 8]. The enzyme
b-secretase generates the amino terminus of Ab, while
c-secretase cleavage at the carboxy-terminus dictates its
length. Ab40 is the most common species and Ab42 the
more fibrillogenic. b-Secretase activity has been attributed
to a single protein, BACE 1 [9], whereas c-secretase
activity depends on four essential components, namely,
presenilin, nicastrin, APH-1, and PEN-2, which together
form a proteolytic complex [10]. a-Secretase is the enzyme
that is involved in the non-amyloidogenic pathway, by
cleaving APP within the Ab domain and thus precluding
Ab formation [11].
The second histopathological hallmark of AD are the
neurofibrillary lesions that are found in cell bodies and
apical dendrites as NFTs, in distal dendrites as neuropil
threads, and in the abnormal neurites that are associated
with some plaques (neuritic plaques). NFTs are also
abundant, in the absence of overt plaques, in over two
dozen tauopathies that represent a significant subset of
FTD [12]. The neurofibrillary lesions are mainly composed
of highly phosphorylated, aggregated assemblies of the
protein tau [13, 14]. Tau belongs to the family of micro-
tubule-associated proteins (MAPs) that includes MAP2. As
neurons develop, tau segregates into axons, and MAP2 into
dendrites [15]. In the axon, tau stabilizes the microtubules.
Under pathological conditions tau dissociates from the
microtubules, causing them to collapse, and tau starts
accumulating in the somatodendritic compartment. The
precise steps of this process are not fully understood. The
established axonal localization of tau does not exclude the
fact that under physiological conditions, this protein exerts
Fig. 1 Histopathological and genetic features of Alzheimer’s disease
(AD) and frontotemporal dementia (FTD). Memory impairment
characterizes AD at a clinical level, and the presence of amyloid
(Ab) plaques and phospho-tau-containing neurofibrillary tangles
(NFTs) in brain at a histopathological level. A unifying feature of
the plaques and tangles is that their major proteinaceous components,
Ab and tau, respectively, are fibrillar. Plaques are scarce in FTD. The
prominent feature in FTD is a behavioral impairment, with memory
functions often being preserved until late in disease. Compared to
AD, FTD is a highly heterogeneous group of related dementias, as
reflected both by the function of the mutated genes, by the proteins
that are deposited as insoluble aggregates, and by the clinical
syndromes, with language and behavioral variants known. A subset of
FTD, known as frontotemporal lobar degeneration with tau deposits
(FTLD-T) or FTD with Parkinsonism linked to chromosome 17
(FTDP-17), is characterized by tau inclusions. The first FTD
mutations were identified in the tau-encoding MAPT gene causing
FTLD-T. Mutations have been subsequently identified in the PGRN
gene encoding progranulin, and in the VCP gene encoding valosin-
containing protein. TDP-43 is the deposited protein, and these
deposits are shared with motor neuron disease (MND), also known as
amyotrophic lateral sclerosis (ALS). Fused in sarcoma (FUS) is
another pathological protein that has been identified in a small subset
of patients with either ALS or a form of FTD. In familial AD (FAD),
mutations have been identified in the APP gene encoding the amyloid
precursor protein from which Ab is derived by proteolytic cleavage,
and in the genes encoding presenilin 1 and 2 (PSEN1 and PSEN2),
which form part of the Ab cleavage machinery. In AD, no mutations
have been identified in the tau-encoding MAPT gene
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important functions outside of the axon, such as in the
dendrite, as we have recently shown [16].
Tau contains an unusually high number of putative
phosphorylation sites (45 serines, 35 threonines, and 4
tyrosines), and for many of these, specific antibodies are
available [17]. Under physiological conditions, there are on
average 2–3 mol of phosphate per mol of tau, whereas
under pathological conditions this ratio is increased to
7–8 mol [18]. This posttranslational modification has been
termed ‘hyperphosphorylation’: some sites are phosphor-
ylated to a higher degree in the diseased than in the healthy
brain; others are de novo phosphorylated. Phosphorylation
tends to dissociate tau from microtubules. Tau also
undergoes a conformational change that is likely to assist in
differential phosphorylation [19]. Both tau and Ab undergo
nucleation-dependent fibril formation [20]. In the course of
this process, initially dispersed polypeptide chains slowly
come together to form a diverse array of fibrillation nuclei
that enable the rapid outgrowth into higher order assem-
blies, including fibrils [21–23]. Tau is generally perceived
as a neuronal protein; however, in tauopathies such as
progressive supranuclear palsy (PSP) or corticobasal
degeneration (CBD), the protein forms aggregates in non-
neuronal cells [24], emphasizing the important role of glia
in neurodegenerative disease [25].
In AD, the most severe neuropathological changes occur
in the hippocampal formation, followed by the association
cortices and subcortical structures, including the amygdala
and the nucleus basalis of Meynert [26]. NFTs develop and
spread in a predictable manner across the brain, providing
the basis for distinguishing six stages of disease progres-
sion: the transentorhinal Braak stages I–II represent
clinically silent cases; the limbic stages III–IV, incipient
AD; the neocortical stages V–VI, fully developed AD. By
using phosphorylation-dependent anti-tau antibodies, such
as AT8, neuronal changes can be visualized well before the
actual formation of NFTs [27, 28]. In FTD, there is atrophy
of the frontal and temporal cortex that is often
asymmetrical.
Genetic causes of AD and FTD
What is causing AD is not understood, with the exception
of the rare, familial (FAD) forms; the latter, however,
account for less than 1% of all cases [29]. In FAD, auto-
somal dominant mutations have been identified in three
genes: in APP itself, and in the presenilin 1- (PSEN1) and
presenilin 2-encoding (PSEN2) genes (Fig. 1). In addition
to the FAD genes, a series of susceptibility genes have been
identified in sporadic AD (SAD); these include apolipo-
protein E (APOE) as the most established risk gene
[30] CLU encoding clusterin, PICALM encoding the
phosphatidylinositol-binding clathrin assembly protein,
and CR1 encoding the complement component (3b/4b)
receptor 1 [31–33]. Clinically and histopathologically,
early-onset FAD cannot be discriminated from late-onset
SAD [24].
Compared to AD, FTD is a highly heterogeneous group
of related dementias, as reflected both by the function of the
mutated genes, by the proteins that are deposited as insol-
uble aggregates, and by the clinical syndromes, with
language and behavioral variants known [34]. The first FTD
mutations were identified in FTDP-17 (FTD with Parkin-
sonism linked to chromosome 17) in the tau-encoding
MAPT gene [35–37]. This subset of FTD, also known as
FTLD-T (frontotemporal lobar degeneration with tau
deposits) is characterized by tau inclusions (Fig. 1). There
is also a subset of FTD that lacks tau aggregates but presents
with an abundance of ubiquitin-positive lesions. The nature
of the aggregating protein was not known until recently.
This ‘dementia lacking distinctive histology’ (now termed
FTLD-U or FTDU-17) is caused by loss-of-function
mutations in the PGRN gene that encodes the pleiotropic
protein progranulin, and in the VCP gene that encodes
valosin-containing protein [38, 39]; the aggregating protein
is TDP-43 (TAR DNA-binding protein 43), a highly
conserved heteronuclear ribonucleoprotein (hnRNP) [40].
Fused in sarcoma (FUS) is another pathological protein that
has been identified in a small subset of patients with either
amyotrophic lateral sclerosis (ALS) or a form of FTD [41].
Finally, mutations in CHMP2B that encodes chromatin-
modifying protein 2B cause FTD in the absence of either tau
or TDP-43 inclusions [42]. For detailed information and an
update on the genes and mutations in familial AD and FTD,
we refer the reader to two websites—http://www.molgen.
ua.ac.be/ADMutations and http://www.molgen.ua.ac.be/
FTDMutations—both of which are continually updated
resources.
Clinical features of AD and FTD
The accurate differential diagnosis of AD and FTD remains
a difficult yet important clinical issue, particularly with the
advent of treatments that are designed to target the causes
and/or consequences of specific types of dementia [43].
With the recent advent of positron emission tomography
(PET) imaging, it has become possible to assess Ab
deposition longitudinally and explore its relationship with
cognition and disease progression. For example, in one
study that involved over 200 subjects and a 20-month
clinical follow-up after [11C]Pittsburgh compound B (PiB)-
PET and two additional follow-ups for up to 3 years with
lower numbers of subjects, at baseline, 97% of AD, 69% of
mild cognitive impairment (MCI), and 31% of healthy
Modes of Ab toxicity in Alzheimer’s disease 3361
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control (HC) subjects showed high PiB retention [44]. At
the 20-month follow-up, small but significant increases in
PiB standardized uptake value ratios were observed in the
AD and MCI groups, as well as in the HCs with high PiB
retention at baseline (5.7, 2.1, and 1.5%, respectively).
There was a weak correlation between PiB increases and
the decline in cognition when all groups were combined.
Progression to AD occurred in 67% of MCI with high PiB
versus 5% of those with low PiB, but 20% of the low PiB
MCI subjects progressed to other dementias. Of the high
PiB HCs, 16% developed MCI or AD within 20 months
and 25% by 3 years. One low PiB HC developed MCI.
Taken together, these results indicate that Ab deposition
increases slowly from cognitive normality to moderate
severity AD. Extensive Ab deposition precedes cognitive
impairment and is associated with a higher risk of cognitive
decline in HCs and progression from MCI to AD over
1–2 years. Importantly, the cognitive decline is only weakly
related to the change in Ab plaque burden, suggesting that
downstream factors have a more direct effect on symptom
progression [44]. One of these down-stream factors may
well be differences in protein levels of tau, with low levels
conferring protection [45].
AD is characterized by deficits in memory, visuospatial
ability, language, and executive function. While cognitive
deficits have traditionally been emphasized in defining AD,
there are a variety of neurobehavioral symptoms that are also
commonly associated with the disease, including increased
apathy, agitation, anxiety, and psychiatric symptoms, such
as delusions or hallucination [46]. In contrast to AD, which
is predominantly characterized by memory loss, FTD is
mainly initiated by behavioral impairment (Fig. 1). The
neurobehavioral symptoms include overeating, apathy or
euphoria, disinhibition, depression, stereotyped behaviors,
reduced empathy, and antisocial and aggressive behaviors.
Patients with FTD also show a variety of cognitive prob-
lems, such as language and memory impairments, which are
often coupled with a lack of insight into these changes [47].
In a significant subset of FTD, late Parkinsonism is
found [12]. The diagnosis is based on the person’s clinical
presentation, the medical history and examination, neuro-
psychological assessments and, increasingly, brain imaging.
However, due to its insidious and gradual onset, the diag-
nosis of FTD can be difficult. Furthermore, the behavioral
symptoms, such as apathy or impulsive responding, that are
associated with FTD can have a negative impact on cogni-
tive performance, and patients may be quite often wrongly
diagnosed with AD [48]. At present, AD and FTD can only
be definitively diagnosed at autopsy. The average age of
diagnosis of FTD is about 60 years, which is in the order of
10 years before the average SAD patient is diagnosed
[49, 50].
Animal models of AD and FTD
To better understand the role of Ab and tau in AD and
related disorders, experimental animal models have been
developed, in particular in mice, that reproduce the major
aspects of the neuropathological characteristics of these
diseases [11, 51]. Massive neuronal cell loss, however, has
only been achieved for a small subset of mouse strains.
In 1995, Games and coworkers established the first Ab
plaque-forming mouse strain through expression of the
disease-linked V717F mutant form of APP in the brain,
under control of the platelet-derived growth factor mini-
promoter. These PDAPP mice showed many of the path-
ological features of AD, including extensive deposition of
extracellular amyloid-b plaques, astrocytosis, and neuritic
dystrophy [52]. Similar features were observed in the
Tg2576 strain established by Hsiao and coworkers, by
expressing the APPsw mutation inserted into a hamster
prion protein cosmid vector [53]. The plaque-forming
APP23 strain was established by expressing APPsw under
the control of the neuronal mThy1.2 promoter [54, 55]. The
common features of these strains is the development of
amyloid plaques that are associated with memory impair-
ment [11]. Subsequently, many other models have been
developed with a pronounced plaque pathology, such as the
TgCRND8 or the J20 mice [56, 57].
In the same year in which the first plaque-forming
mice were established, the first tau transgenic mouse
model was also generated, by expressing the longest
human wild-type brain tau isoform, htau40, under control
of the neuronal hThy1 promoter [58]. Despite the lack of
an NFT pathology, the mice reproduced the somatoden-
dritic localization of hyperphosphorylated tau in AD.
They presented a pathology that is best described as an
early ‘pre-tangle’ phenotype. A more pronounced tau
phenotype was eventually achieved through the use of
stronger promoters [59–62]. NFT formation, however,
was only reproduced in mice in 1998, following the
identification of pathogenic FTDP-17 mutations in the
MAPT gene, by targeting FTD mutant tau expression to
both neuronal and glial cells [11]. Our group, for exam-
ple, expressed two mutant forms of tau, G272V and
P301L, in separate strains that both developed NFTs
[63–67], while mice with pseudophosphorylated tau fail to
develop NFTS [68]. The P301L tau-expressing pR5 mice
showed a behavioral impairment in amygdala- and hip-
pocampus-dependent tasks; aspects of the behavioral
impairment could be correlated with the aggregation
pattern of the transgene [67, 69–71]. K369I transgenic
mice, on the other hand, model Parkinsonism in FTD, in
parts owing to expression of the transgene in the
substantia nigra, among other brain areas [72, 73].
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To achieve a more complete model of AD, the plaque
and NFT pathology has been combined in 3xtg-AD mice
that express APPsw and P301L-tau expression on a mutant
PS1M146V knock-in background [74, 75]. These mice have
been used extensively to dissect pathogenic mechanisms
and more recently for gene therapeutic approaches [76].
Remarkably, cognitive function is improved without
altering Ab or tau pathology. Instead, the mechanism
underlying the improved cognition involves a robust
enhancement of hippocampal synaptic density, mediated
by brain-derived neurotrophic factor (BDNF). Another
model with combined pathologies addresses the role of
tau phosphorylation at the pathogenic epitope S422 [77].
These tripleAD mice have been used by us to assess the
effects of Ab and tau on mitochondrial functions (Fig. 2a)
[78].
Ab and down-stream signaling
The amyloid cascade hypothesis claims, in simplistic
terms, that there is a pathogenic degenerative cascade in
AD, with Ab being upstream of tau [79]. To address the
interaction of Ab and tau [80], Ab plaque-forming Tg2576
mice were crossed with NFT-forming P301L tau-trans-
genic JNPL3 mice [65, 81]; also, P301L tau transgenic pR5
mice were intracerebrally injected with fibrillar prepara-
tions of Ab42. Both strategies caused an increased tau
phosphorylation at pathological epitopes and increased
NFT formation, thereby establishing a link between Ab and
tau in vivo [65, 81]. These findings have been reproduced
in vitro [82, 83]. Similarly, NFT formation was aggravated
by infusing brain extracts of aged plaque-forming APP23
mice intracerebrally in P301L tau transgenic mice or by
Fig. 2 Modes of Ab toxicity as
illustrated for the signaling
through the NMDA (N-methyl
D-aspartate) receptor (NMDAR).
Tau is perceived as an ‘axonal’
protein, although a fraction of it
is present in dendrites. Tau
functions in targeting the kinase




formation of NMDARs with the
post-synaptic density protein 95
(PSD95). The over-activation of
the NMDAR complex
(excitotoxicity) results in
excessive nitric oxide (NO)
levels. This causes down-stream
protein misfolding and
aggregation, as well as
mitochondrial fragmentation.
The toxic signaling pathway
also involves the release of
mitochondrial cytochrome c
(Cyt c) and the activation of
down-stream caspases as well as
the formation of reactive
oxygen species (ROS). The
excitotoxicity complex mediates
Ab’s toxic functions and
subsequent neurodegeneration,
a process that depends on the
presence of tau. Inset:
Components of the
mitochondrial respiratory chain
itself are targets of Ab and tau
and, together, these toxic
entities synergistically impair
mitochondrial functions
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crossing Ab plaque-forming APP23 and P301L tau trans-
genic mice [84]. Together, these studies established that
Ab exaggerates a pre-existing tau pathology supporting, at
least in part, the amyloid cascade hypothesis in mice. They
proved an essential role for Ab in disease.
However, there is also an important role for tau. When
hippocampal neurons from tau knockout and transgenic as
well as wild-type control mice were cultured in the pres-
ence of Ab, it was found that the knockout neurons were
resistant to Ab toxicity, while those from tau transgenic
mice were more susceptible [85]. In a next step towards
showing an essential role for tau in mediating Ab toxicity,
Mucke and colleagues crossed plaque-forming APP trans-
genic mice onto hetero- and homozygous tau knockout
backgrounds [86]. They found that this prevented the
memory impairment that characterizes the APP mutant
mice and, importantly (and somewhat surprisingly), that
this improvement was achieved without any changes to Ab
levels or Ab plaque load. Tau reduction also protected
against pentylenetetrazole (PTZ)-mediated excitotoxicity,
as shown by a reduced seizure severity and increased
latency. Excitotoxicity describes a signaling cascade that is
induced by the over-activation of the N-methyl-D-aspartate
(NMDA) receptor (NMDAR), resulting in neuronal dam-
age and death due to the generation of excessive nitric
oxide (NO) (Fig. 2). This process has been implicated as
one patho-mechanism underlying Ab-mediated neurode-
generation in AD, despite a lack of evidence for a direct
binding of Ab to NMDARs [87, 88]. Toxicity mediated by
any particular receptor may not necessarily involve the
direct binding of Ab, but it could be due to an indirect
modulation of receptor properties, possibly through mem-
brane association. This mechanism may explain why Ab
has been reported to bind to distinct receptors under certain
conditions and not to others depending on the experimental
design [89, 90]. Results from recent studies suggest that
excessive NO can mediate excitotoxicity in part by trig-
gering down-stream protein misfolding and aggregation, as
well as mitochondrial fragmentation. S-Nitrosylation, or
covalent reaction of NO with specific protein thiol groups,
represents a convergent signal pathway contributing to NO-
induced protein misfolding and aggregation, as well as
mitochondrial fragmentation through Ab-related S-nitro-
sylation of proteins, such as dynamin-related protein-1
(Drp1) [91]. The toxic signaling pathway also involves the
release of mitochondrial cytochrome c and the activation of
down-stream caspases [92, 93]. Excessive NMDAR acti-
vation thus precipitates the neuronal degenerative process,
in part by mitochondrial dysfunction [94].
Coming back to the interaction of tau and Ab, the
important question arises how tau in fact mediates Ab
toxicity and why its removal prevents it? In order to
decipher the underlying mechanisms, we generated a
mouse strain that expresses the projection domain of tau,
while lacking the microtubule-binding domain [16]. When
these so-called Dtau mice were crossed with Ab plaque-
forming APP23 mice, the high susceptibility to excitotox-
icity that characterizes the APP23 strain was rescued; also
rescued was early mortality. In addition, the memory
phenotype of these mice improved; and again, the res-
cue occurred in the absence of any changes to APP
mRNA levels, or Ab plaque load. Similarly, crossing the
APP23 mice onto a second tau knockout background
confirmed the previous findings of Mucke and colleagues
on the protective role of not having tau [16, 86]. When we
analyzed the subcellular localization of the projection
domain tau in Dtau mice, we found that it accumulated in
the soma, while it was excluded from the dendrite. What
links tau and the NMDAR is the non-receptor tyrosine
kinase Fyn, establishing a toxic triad [95]. We found by
enhanced immunohistochemistry that already under phys-
iological conditions a fraction of tau is present in the
dendrites (Fig. 2) [16]. It functions in targeting the kinase
Fyn to the dendrite where the enzyme phosphorylates the
NMDAR subunit NR2B, thereby mediating complex for-
mation of the NMDAR with the post-synaptic density
protein 95 (PSD95) [96]. In the presence of Dtau, this
truncated version of tau competes with endogenous (full-
length) tau in the binding to Fyn, trapping it in the soma
and preventing it from entering the dendrites. Therefore,
Fyn is not available for phosphorylation of NR2B’s Y1472
and hence, the excitotoxic signaling complex cannot be
formed. Likewise, in tau knockout mice, tau is not avail-
able in the first place, and Fyn is thus not targeted to the
dendrite. While excitotoxic signaling is impaired in Dtau
over-expressing or tau knockout mice, we found no sig-
nificant changes in synaptic NMDAR expression levels and
NMDA currents [16]. In addition to the genetic approach,
we tested the pharmacological uncoupling of the NMDAR/
PSD95 complex in APP23 mice by delivering a small
peptide, Tat-NR2B9c, composed of the carboxy-terminal
amino acids of NR2b (including Y1472) fused to a HIV1-
Tat peptide [97], using an osmotic pump. This approach
permanently protected the APP23 mice from experimen-
tally induced seizures and memory impairment and
extended their lifespan to that of wild-type mice. However,
crossing the APP23 mice with P301L tau mutant pR5 mice
that are characterized by tau accumulation in the soma and,
importantly, in the dendrites, caused a dramatic effect in
that none of the mice survived beyond the age of 4 months
[16]. Tau reduction has subsequently been shown to further
prevent the Ab-induced defects in the axonal transport of
mitochondria [98].
Together, these findings lead us to propose the ‘tau axis
hypothesis’ [45] which postulates that progressively
increasing levels of dendritic tau make neurons more
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vulnerable to Ab: at the onset of AD, Ab levels in the
brain increase. The presence of tau at low levels in the
dendrites (low compared to levels in the axon) renders, to
some degree, the dendrites (and their spines) vulnerable
to postsynaptic Ab toxicity (Fig. 2b). With disease
progressing, tau becomes increasingly phosphorylated (a
process driven in part by Ab), and tau accumulates in the
soma and the dendrites. In fully manifested AD, levels of
tau in the dendrite (dendritic spine) are high, and this is
associated with an increased neuronal vulnerability to Ab
toxicity. As Ab increases further, it exacerbates tau’s
phosphorylation and somatodendritic accumulation,
thereby hypersensitizing the synapses to Ab’s toxicity.
Ultimately, this process results in the loss of synapses and
causes neuronal degeneration [6]. There is an increasing
understanding that in AD the neuronal network is dis-
turbed and as the disease is initiated at one particular site,
it is spreading through the brain via synaptic connections.
This concept has been addressed in mice by targeting
transgene expression to distinct subregions of the brain,
such as the entorhinal cortex (EC) [99]. In this brain area,
NFT formation was found to be initiated in AD. Trans-
genic overexpression of APP/Ab in the EC elicited
abnormalities in synaptic functions and activity-related
molecules in the hippocampal dentate gyrus and CA1
regions, as well as epileptiform activity in the parietal
cortex. Soluble Ab was observed in the dentate gyrus, and
Ab deposits in the hippocampus were localized to ter-
minal fields of the perforant pathway. Thus, the authors
concluded that APP/Ab expression in EC neurons causes
transsynaptic deficits that may initiate a cortico-hippo-
campal network dysfunction in both mouse models and
human patients with AD [99].
What is the identity of the Ab receptor(s) and what are
the down-stream effectors of its toxicity? At present it is
not understood whether Ab acts via a receptor or whether
membrane binding alone is sufficient [100]. If Ab acts via a
receptor, this receptor may have specificity for Ab or it
may bind proteins or peptides with shared amyloid prop-
erties. Work on primary cortical and hippocampal cultures
treated with the amyloidogenic peptides Ab and human
amylin, respectively, indicates that the latter may be the
case, as rat amylin, which is not amyloidogenic, turns out
not to be toxic, while both Ab and human amylin are [101].
These findings underscore commonalities between AD and
type 2 diabetes mellitus [102]. Membrane interaction of Ab
can occur via its hydrophobic carboxy-terminal domain
[103, 104] or by electrostatic interactions mediated by the
charged amino acids in the amino-terminal domain [105].
Ab may bind to the cell membrane to form channels or
pores that disrupt ion homeostasis, hence leading to neu-
ronal dysfunction [103, 106–109]. As several molecules
associated with disease, such as the Prion protein, the
British peptide, or human amylin, can form soluble oligo-
mers, bind to membranes, and subsequently disrupt ion
homeostasis, this may be an inherent property of amyloi-
dogenic proteins or peptides [110].
As discussed above, toxicity mediated by the NMDAR
may not necessarily involve direct binding of Ab, rather it
could be due to an indirect modulation of receptor prop-
erties, possibly through membrane association [89, 90].
Normal NMDAR signaling is a multi-step process, with
contributions by the fast acting nuclear Ca2?/calmodulin-
dependent protein (CaM) kinase pathway and the slower
acting, longer lasting Ras-extracellular signal-regulated
kinase 1/2 (ERK1/2) pathway, which translocate to the
nucleus and ultimately result in activation of the trans-
cription factor CREB [111]. Too much calcium influx via
the NMDAR, such as under excitototoxic conditions, leads
to neuronal death. While a long-standing view is that
neuronal responses to NMDAR activity follow a bell-
shaped curve, in which both too much and too little
response is potentially harmful, this view has been recently
revisited in that the location of the NMDAR may influence
whether its activation is coupled to pro-death or pro-sur-
vival signals [111].
Ab may induce synaptic and neuronal degeneration via a
plethora of pathways [112]. Ab’s anti-LTP (long-term
potentiation) activity can be modulated by antagonists of
the p38 MAP kinase [113] and the Jun NH2-terminal
kinase (JNK) pathways [114], both of which have been
implicated in the hyperphosphorylation of tau [115, 116].
In one study, inhibitors of p38, JNK, GSK-3b, and phos-
phatidylinositol 3-kinase showed either no or only minor
inhibition of Ab oligomer-mediated cell death in mouse
hippocampal slices, but inhibitors of MAPK kinase kinase
(MAPKKK), which is upstream of the extracellular ERKs,
significantly inhibited Ab-mediated neuronal death [117].
Another interesting kinase is Fyn, as it links Ab and tau
[45]. Not only is Fyn an interaction partner of tau [118], it
also phosphorylates tau at Y18 [119]. Fyn is necessary for
the toxicity of Ab-derived diffusible ligands (ADDL, an
oligomeric form of Ab) as Fyn knockout neurons are
resistant to ADDL-mediated neuronal cell death [120].
Moreover, when crossed with APP transgenic mice, Fyn
knockout mice display reduced synaptotoxicity without
affecting aberrant sprouting [121, 122]. Fyn has a role in
modulating synaptic activity and plasticity through its
phosphorylation of NMDAR [123]. While tau reduction
prevents cognitive deficits in Ab-forming APP transgenic
mice, Fyn overexpression exacerbates them.
Using electroencephalography (EEG) to examine net-
work effects, researchers have recorded whole-cell currents
in acute hippocampal slices from APP mice in the presence
or absence of tau. APP mice with tau had increased
spontaneous and evoked excitatory currents, reduced
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inhibitory currents, and NMDAR dysfunction. Tau
reduction increased inhibitory currents and normalized the
excitation/inhibition balance and NMDAR-mediated
currents in the APP mutant mice [124]. These findings are
consistent with the fact that Ab oligomers alter the
transport of NMDAR by promoting its endocytosis,
resulting in decreased receptor activity both in vitro and
in the APP transgenic mice [125]. Work on neuronal and
astrocyte cultures further suggests that Ab causes Ca2?-
dependent oxidative stress by activating an astrocytic
NADPH oxidase, with neuronal death following through a
failure of antioxidant support [126]. Together, these
results suggest a fine-balanced network of molecular
interactions [100].
Neurotoxicity of different Ab species
Alzheimer’s disease is believed to be a disease of the
synapses and has hence been termed a ‘synaptic failure’
[6]. While Ab can kill neurons, synaptotoxicity may be
more relevant for the earlier stages of AD that are best
characterized by synaptic loss rather than neuronal death.
Loss of synaptic terminals or dendritic spines could cause
the associated decline in cognitive functions that charac-
terizes AD. Whether the neurotoxic and synaptotoxic
actions of Ab are separate activities or whether they share
common mechanisms is not known [100].
The interpretation of Ab toxicity studies is complicated
by the fact that different preparations are being used, such
as Ab42 versus the less amyloidogenic Ab40 versus the
shorter, cheaper Ab25-35 version, aged versus fresh prep-
arations, monomers versus oligomers versus fibrils; on top
of that, different concentrations, incubation times, and
cellular system add additional levels of complexity [127,
128]. For example, it was found early on that while
Ab peptide added at micromolar concentrations to
primary neuronal cultures induces cell death [129], low,
subnanomolar concentrations are neurotrophic, arguing in
favor of a physiological function of Ab [129]. When Ab
aggregation was induced, this aggregation increased the
neurotoxic activity of the Ab peptide, suggesting that the
toxic species are associated with the formation of fibrils
[130–132]. At present, however, major research efforts of
many groups concentrate on non-fibrillar soluble Ab as the
major toxic species in AD [120, 133–135]. These have
been given different names, including ADDLs [120],
globulomers [136], and the dodecameric Ab species Ab*56
[137]. Recent structural analysis has revealed that penta-
meric and hexameric oligomers may be the building blocks
of the more toxic decameric and dodecameric complexes
[138]. To assist in identifying the different Ab species,
conformational antibodies have been developed that not
only stabilize the Ab protofibrils but also prevent mature
amyloid fibril formation [135, 139].
Ab can inhibit long-term potentiation (LTP), a model
system for synaptic strengthening and memory [120, 133,
140–142]. When cell medium containing abundant Ab
monomers and putative oligomers—but not amyloid
fibrils—was microinjected into rat brain, this markedly
inhibited hippocampal LTP [133]. Immunodepletion of all
Ab species from the medium completely abrogated this
effect. Pretreatment of the medium with insulin-degrading
enzyme (IDE), which degrades Ab monomers but not
oligomers, did not prevent the inhibition of LTP, indicating
a crucial role for Ab oligomers. These were shown to
disrupt synaptic plasticity in vivo at concentrations found
in the human brain and cerebrospinal fluid, in the absence
of monomeric or fibrillar amyloid. When cells were treated
with c-secretase inhibitors at doses which prevented
oligomer formation but allowed appreciable monomer
production, LTP was not longer inhibited, indicating that
synaptotoxic Ab oligomers can be targeted therapeutically
[133, 143]. Oligomers caused a tenfold greater toxicity in
Neuro-2A cells than in fibrils [144]. However, whereas
LTP seems to be inhibited by oligomeric Ab only and not
by fibrillar Ab, in a different experimental paradigm, the
two species seem to have both toxic, yet diverse effects
[145]. Using rat astrocyte cultures, oligomeric Ab42 was
shown to induce initial high levels of the pro-inflammatory
molecule interleukin (IL)-1b that decreased over time,
whereas fibrillar Ab caused increased levels over time
[145]. With respect to mitochondrial functions, we
observed that fibrillar and oligomeric species demonstrated
a very similar degree of toxicity (see below). It has been
suggested that the neurotoxic activity of oligomers is
associated with dimeric and trimeric species [133, 142]
and, in a recent study, Ab dimers were found to be the most
abundant form of soluble oligomer detectable in the human
brain [146]. They were isolated from the cortices of typical
AD subjects, at subnanomolar concentrations, they first
induced tau hyperphosphorylation in hippocampal neurons,
subsequently disrupting the microtubule cytoskeleton, and
they caused neuritic degeneration—all in the absence of
amyloid fibrils.
The relative contribution of the two forms of Ab—Ab40
and Ab42—to disease is a matter of debate. One of the
major puzzles in the AD field is that a difference of just
two residues between Ab40 and Ab42 markedly changes
toxicity and aggregation properties. A structural study
showed that the hydrophobic carboxy-terminal residues in
Ab42 stabilize the neurotoxic low-order oligomers in a
non-b-sheet secondary structure and that the conversion to
protofibrils and fibrils having b-sheet secondary structure
reduces toxicity [138]. In Drosophila, Ab42 expres-
sion causes the formation of diffuse amyloid deposits,
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age-dependent learning deficits, and neurodegeneration.
Ab40 causes similar learning deficits without aggregation
and neurodegeneration [147]. On the other hand, rational
mutagenesis applied to the Ab42 peptide confirmed that the
rate of aggregate formation in vitro is linked to brain
toxicity [148]. Furthermore, flies expressing wild-type or
E22G Ab42 had a median survival of 24 and 8 days,
respectively, whereas Ab40-expressing flies had a median
survival of 30 days, indicating that Ab40 may be
non-toxic, and possibly protective [147]. This possibility is
supported by nuclear magnetic resonance (NMR) studies
which revealed that Ab40 prevents Ab42 from aggregating
in vitro [149]. Thus, this aspect of toxicity and the relative
role of monomeric, oligomeric, and fibrillar species are far
from being resolved.
Ab-binding proteins and mitochondrial targets
A number of Ab-binding proteins have been identified on
the outside of the plasma membrane of neurons and glial
cells that are limited to dealing with a highly sticky pep-
tide, such as Ab42. These proteins include the a7-nicotinic
acetylcholine receptor, the receptor for advanced glyco-
sylation end-products (RAGE), APP itself, NMDAR, the
P75 neurotrophin receptor (P75NTR), CD36, and low-
density lipoprotein receptor-related protein (LRP) members
[150]. LRP, apoE, and the serum protein a2-macroglobulin
(a2M) probably modulate Ab toxicity via clearance of
apoE:Ab and a2M:Ab complexes or Ab alone from the
brain and hence reduce Ab levels [151, 152]. Interestingly,
in a study involving metabolic labeling, Ab clearance rates
were found to be relatively impaired in the central nervous
system (CNS) of AD patients compared with controls,
while production was unaffected [153]. Specifically, late-
onset AD was associated with a 30% impaired clearance of
both Ab42 and Ab40, indicating that clearance mecha-
nisms may be critically important in the development of
AD. Estimates based on a 30% decrease in Ab clearance
rates suggest that the AD brain accumulates Ab over a
period of about 10 years. The impaired clearance of both
Ab40 and Ab42 is consistent with prior findings of the
deposition of both Ab40 and Ab42 in parenchymal
amyloid plaques and the substantial deposition of Ab40 in
cerebral amyloid angiopathy in about 80% of cases of AD
[154].
P75NTR can bind a variety of Ab oligomeric species
and modulate Ab toxicity in a cell type- and P75 isoform-
dependent manner [155, 156]. Full-length P75NTR blocks
toxicity of both fibrillar and non-fibrillar Ab preparations
in primary neuronal cultures [157], but promotes toxicity of
fibrillar Ab in neuroblastoma cells [158]. The binding of
Ab oligomers to neurons can be blocked with an anti-
NMDAR antibody and, as a consequence, reactive oxygen
species (ROS) stimulation in hippocampal cultures is
reduced [159]. These results indicate different modes of
toxicity in different cell types.
There is an increasing amount of data being published
on intracellular sites of Ab production and targeting,
including intracellular organelles, such as mitochondria
[160–164], whose function it impairs [165–169]. When we
analyzed the total brain proteome of P301L tau transgenic
pR5 and wild-type mice, we discovered that it consisted
mainly of metabolically related proteins, including
mitochondrial respiratory chain complex components,
antioxidant enzymes, and synaptic proteins, that were
modified. This deregulation could be functionally validated
in the pR5 mice as mitochondrial dysfunction, and the
reduction in mitochondrial complex V levels was
confirmed in human P301L FTDP-17 brains [166]. In one
study, we found that P301L tau mitochondria displayed an
increased vulnerability towards fibrillar Ab42 compared to
control mitochondria, suggesting a synergistic action of tau
and Ab pathology on the mitochondria [166]. In a follow-
up study we investigated the toxicity of oligomeric Ab
species [127, 128]. Interestingly, in cortical pR5 brain
cells, both oligomeric and fibrillar—but not monomeric—
Ab42 caused a decreased mitochondrial membrane poten-
tial. This was not observed with cerebellar preparations,
indicating selective vulnerability of cortical neurons [167].
We also measured reductions in state 3 respiration, the
respiratory control ratio, and uncoupled respiration when
P301L tau mitochondria were incubated with either oligo-
meric or fibrillar preparations of Ab42. We found that
aging specifically increased the sensitivity of mitochondria
to oligomeric Ab42 damage, indicating that while oligo-
meric and fibrillar Ab42 are both toxic, they exert different
degrees of toxicity in mitochondria from older animals
[167]. When we performed a comparative, quantitative
iTRAQ proteomic analysis of single-transgenic pR5, dou-
ble-transgenic APP/PS2 mutant, and tripleAD (pR5/APP/
PS2) mice, as well as of wild-type controls, we found that
one-third of the deregulated proteins were mitochondrial.
Notably, deregulation of complex I was tau dependent,
while deregulation of complex IV was Ab dependent, both
at the protein and activity levels. Synergistic effects of Ab
and tau were evident in 8-month-old tripleAD mice as only
they showed a reduction of the mitochondrial membrane
potential at this early age. At the age of 12 months, the
strongest defects on the oxidative phosphorylation system,
the synthesis of ATP, and ROS levels were exhibited in the
tripleAD mice, again emphasizing synergistic, age-associ-
ated effects of Ab and tau in perishing mitochondria [78].
Synergistic effects were also found by us in the neuro-
blastoma cell system in promoting aberrant cell cycle
reentry [170].
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Mitochondrial dysfunction has been linked to full-length
and carboxy-terminally truncated APP, which was shown
to accumulate exclusively in the protein import channels of
mitochondria of human AD, but not age-matched control
brains [163]. Similarly, the accumulation of full-length
APP in the mitochondrial compartment in a transmem-
brane-arrested form, but not lacking the acidic domain, was
shown to cause mitochondrial dysfunction and impair
energy metabolism [171]. Ab can disrupt mitochondrial
cytochrome c oxidase activity [161, 172] in a sequence-
and conformer-dependent manner [161]. The Ab binding
protein alcohol dehydrogenase (ABAD, also known as
ERAB) is a short-chain alcohol dehydrogenase that binds
to Ab in the mitochondrial matrix. ABAD can bind to
oligomeric Ab42 present in the cortical mitochondria
of APP transgenic mice [173]. This interaction pro-
motes leakage of ROS, mitochondrial dysfunction, and
cell death—potentially underlying the mechanism of
Ab-induced mitochondrial toxicity [160]. The results of
protease sensitivity assays suggest that Ab indeed gains
access to the mitochondrial matrix rather than being simply
adsorbed to the external mitochondrial surface [162]. The
interaction between Ab and mitochondria may explain how
Ab induces apoptosis and caspase activation [160, 174,
175]. In general, intracellullar Ab may be derived either
from internalized extracellular Ab or from intracellularly
generated Ab [176–178]. As it stands, the putative exis-
tence of intracellular Ab adds a further level of complexity
to the mechanism of Ab toxicity, obtaining direct access to
organelles that are vital for the function and viability of
neurons [179].
Ab, altered gene expression and miRNA deregulation
The last years have seen vast improvements in the methods
available for functional genomics studies. The effects of
Ab on the proteome and transcriptome can be assessed
with increasingly smaller sample sizes and a higher sen-
sitivity, and these methods have been applied successfully
to AD and its model systems [180, 181]. Previously, we
and others identified deregulated genes and proteins either
in human AD tissue itself, or in tissue culture systems and
animal models [182–184]. This approach not only identi-
fied deregulated genes and proteins but also pathogenic
mechanisms, such as mitochondrial dysfunction, impaired
unfolded protein responses, and changes in microRNA
(miRNA) expression [185]. MicroRNAs (miRNAs) add
another level of complexity to gene regulation. While ini-
tially identified for their roles in development and cellular
identity, the role of miRNAs in human neurodegenerative
disease has been increasingly acknowledged in more recent
times [186–188]. miRNAs are evolutionarily conserved
non-coding RNAs that are approximately 22 nucleotides
and which negatively regulate gene expression in a
sequence-specific manner [189, 190]. Changes in miRNA
profiles have been reported for postmortem human AD
brain tissue, where they include miRNAs that regulate
genes such as APP itself or BACE1, which encodes the
b-secretase involved in APP processing and Ab formation
[191–194]. Although the role of genes such as APP and
PSEN in familial AD is firmly established, little is known
about the molecular mechanisms affecting Ab generation
in sporadic AD. A deficiency in Ab clearance is a possi-
bility, as discussed above, but an increased expression of
proteins such as APP or BACE1 may also be associated
with the disease: a study of miRNA expression profiles in
sporadic AD patients revealed that several miRNAs
potentially involved in the regulation of APP and BACE1
expression appear to be decreased in the diseased brain. Of
these, miR-29a, -29b-1, and -9 can regulate BACE1
expression in vitro. The miR-29a/b-1 cluster was signifi-
cantly (and AD-specific) decreased in AD patients
displaying abnormally high BACE1 protein. Similar cor-
relations between the expression of this cluster and BACE1
were found during brain development and in primary
neuronal cultures. These results suggest that the loss of
specific miRNAs can contribute to increased BACE1 and
Ab levels in sporadic AD [192]. In a comparison of human
brain tissue to Ab-treated primary neuronal cultures or
brain tissue derived from Ab-depositing APP mutant
APP23 transgenic mice, we found a remarkable overlap in
deregulated, mostly down-regulated miRNAs [185]. The
down-regulation of approximately 50% of the miRNAs
tested in response to Ab was also observed, including
down-regulation of miR-9 and 181c, which are also down-
regulated in human AD brain tissue [192, 195, 196].
Whether changes in miRNA profiles are specific for
sporadic AD, or whether they are a cause or a consequence
of the disease process, remains to be investigated: the
interesting opportunity that is offered, however, is that
miRNAs, similar to protein markers, can be used for
diagnostic purposes [192], as is the case for cancer patients
[197].
Conclusions
What can be expected in the forthcoming years? Some of
the current therapeutic trials targeting Ab may come to
fruition [11]. The mode of Ab uptake and/or binding by
neurons and other cell types will be elucidated and inter-
acting proteins, both under physiological and pathologic
conditions, will be identified. With the advent of new tools,
it will likely become easier to discriminate Ab conforma-
tions and hence allow the role of specific conformers in
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toxicity to be defined [139]. Moreover, the role that tau
plays in mediating Ab toxicity in disease will assist in the
development of treatment strategies for AD and related
disorders [45].
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